HISUN(SH:600267) Cai Jing Wang·2026-01-20 08:29Core Viewpoint - Recently, Zhejiang Hai Zheng Pharmaceutical Co., Ltd. announced corrections to its financial data for the years 2021 to 2024, indicating that previously disclosed financial information was inaccurate and untruthful [1] Group 1: Financial Corrections - The company corrected financial data related to operating revenue, operating costs, and investment income for the years 2021 to 2024 [1] - The announcement was made on August 26, 2025, highlighting the discrepancies in the annual reports [1] Group 2: Accountability and Penalties - The Shanghai Stock Exchange decided to publicly criticize the company and the responsible individuals, including the former chairman and other executives [1] - The penalties will be reported to the China Securities Regulatory Commission and recorded in the securities and futures market integrity database [1] - The company is required to submit a rectification report signed by all directors and senior management within one month of receiving the decision [1]